Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen reported its Q4 2022 revenues at $6.8 billion, nearly unchanged from Q4 2021, with a 4% rise in product sales with 10% volume growth. For the full year, revenues reached $26.3 billion, a 1% increase, driven by a 2% rise in product sales. However, GAAP EPS fell 11% in Q4 to $3.00, despite a full-year increase of 18% to $12.11. Amgen anticipates total revenues between $26.0 billion and $27.2 billion in 2023, while excluding contributions from the acquisition of Horizon Therapeutics.
Amgen announced that AMJEVITA (adalimumab-atto), the first biosimilar to Humira, is now available in the U.S. Approved by the FDA in 2016, AMJEVITA offers a list price 55% lower than Humira. This biosimilar aims to enhance patient access and reduce healthcare costs while treating serious inflammatory diseases. With a history of use in over 300,000 patients across more than 60 countries, AMJEVITA is available in multiple forms. The launch aligns with Amgen's commitment to responsible pricing and patient support.
Amgen (NASDAQ:AMGN) will release its fourth quarter and full year 2022 financial results on January 31, 2023, post-market close. A conference call with management, including CEO Robert A. Bradway, will follow at 4:30 p.m. ET. The call and additional financial presentations will be accessible via the Amgen website.
Amgen, a leader in biotechnology, focuses on developing innovative therapeutics for patients with serious illnesses. The company is recognized as one of the top independent biotech firms and is part of the Dow Jones Industrial Average and Nasdaq-100.
Amgen (NASDAQ:AMGN) has awarded the third Amgen Golden Ticket to Nammi Therapeutics, providing the company with one year of lab space at BioLabs LA at The Lundquist Institute. This initiative aims to accelerate life science startups in Southern California and reflects Amgen's commitment to supporting innovative biotechnology. The award was decided after a competitive pitch event judged by Amgen's scientific leaders, further enhancing the collaborative ecosystem within the Los Angeles biotech community.
Amgen will present at the 2023 J.P. Morgan Healthcare Conference on January 9, 2023, at 6:45 p.m. ET. CEO Robert A. Bradway will lead the presentation, which will be available via a live webcast to media, investors, and the public. The event will also be archived for replay for 90 days. Amgen, a biotechnology pioneer since 1980, focuses on innovative therapeutics for serious illnesses, contributing significantly to health outcomes. The company is part of the Dow Jones Industrial Average and Nasdaq-100, recognized for sustainability and employee satisfaction.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.
Amgen announced groundbreaking results from the Phase 3 E1910 trial, demonstrating that BLINCYTO combined with chemotherapy significantly improves survival for adults with Philadelphia chromosome-negative B-ALL. At 3.5 years, survival rates were 83% for those receiving BLINCYTO plus chemotherapy, compared to 65% for chemotherapy alone. The study, conducted by the ECOG-ACRIN Cancer Research Group, showed a 58% reduction in death risk with BLINCYTO. These findings will be submitted to regulatory authorities. No new safety concerns were noted, reinforcing BLINCYTO's efficacy in treating this challenging cancer.
Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q1 2023, reflecting a 10% increase from previous quarters. The dividend payment date is set for March 8, 2023, with record holders as of February 15, 2023. This positive adjustment demonstrates Amgen's commitment to returning value to shareholders amidst its ongoing developments in innovative therapeutics. The company continues to focus on high unmet medical needs while advancing its production capabilities and product pipeline.
Amgen (NASDAQ:AMGN) announced a webcast for the investment community at 8:00 a.m. ET on December 12, 2022, following its acquisition of Horizon Therapeutics. CEO Robert A. Bradway and the executive team will participate in the call, which will be accessible to media and the public. The event will be archived for 90 days on Amgen’s website. This acquisition highlights Amgen's commitment to addressing serious medical needs and expanding its innovative pipeline of therapeutics.
Amgen has announced a recommended cash offer for Horizon Therapeutics PLC, with Pillartree Limited, a subsidiary wholly owned by Amgen, acquiring Horizon's entire share capital at $116.50 per share. This represents a premium of approximately 47.9% over Horizon's November 29 closing price. The total transaction values Horizon at $27.8 billion, with an enterprise value of $28.3 billion. Amgen plans to finance this acquisition through a $28.5 billion bridge credit agreement, enhancing its portfolio in inflammation and nephrology, and is expected to drive revenue growth starting in 2024.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
